上 市 公 司 医药生物 ——2024 年业绩符合预期，看好公司高端产品放量 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 04 月 30 日 | | --- | --- | | 收盘价（元） | 79.03 | | 一年内最高/最低（元） | 159.80/65.17 | | 市净率 | 6.1 | | 股息率%（分红/股价） | 0.62 | | 流通 A 股市值（百万元） | 14,980 | | 上证指数/深证成指 | 3,279.03/9,899.82 | 注："股息率"以最近一年已公布分红计算 | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产（元） | 12.92 | | 资产负债率% | 24.61 | | 总股本/流通 A 股（百万） | 190/190 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 04-30 05-31 06-30 07-31 08-31 09-30 10-31 11-30 12-31 01-31 02-28 03-31 04-30 -40% -20% 0 ...

Core Viewpoint - Yanjing Beer reported strong financial performance in Q1 2025, with significant profit growth driven by revenue increase and effective cost control [2][4]. Financial Performance - Total revenue and net profit for Q1 2025 were CNY 3.827 billion and CNY 165 million, respectively, representing year-on-year growth of 7% and 61% [2]. - The non-recurring net profit was CNY 153 million, up 49% year-on-year [2]. - Gross margin and net margin improved to 43% and 6%, reflecting increases of 5.6 and 2.3 percentage points year-on-year [2]. - Operating cash flow and sales collection showed robust growth, with operating cash flow at CNY 1.333 billion (up 49%) and sales collection at CNY 4.713 billion (up 10%) [2]. Product Strategy - Beer sales reached 995,000 tons in Q1 2025, with the flagship product Yanjing U8 maintaining over 30% growth [3]. - The company is focusing on high-end products, with brands like "Jiuhao" targeting the raw beer market and "Lion King" aimed at premium craft beer consumers [3]. - The introduction of Beiste soda in March 2025 marks a strategic move into the non-alcoholic segment, enhancing market coverage for dining scenarios like hot pot and barbecue [3]. - The appointment of a brand ambassador has significantly increased market exposure, with discussion volume reaching 330 million across major platforms [3]. Profit Forecast - The company is expected to maintain high profit growth driven by the continued expansion of mid-to-high-end products, particularly U8, and ongoing operational improvements [4]. - EPS forecasts for 2025-2027 are CNY 0.51, CNY 0.62, and CNY 0.75, with corresponding PE ratios of 25, 21, and 17 times at the current stock price [4].